CytomX Therapeutics, Inc.
227 articles about CytomX Therapeutics, Inc.
-
CytomX Announces The First Patient Treated In Phase I/II PROCLAIM-072 Trial
2/2/2017
-
CytomX Announces U.S. FDA Clearance Of Investigational New Drug Application For Phase I/II Clinical Study Of Anti-PD-L1 Probody Therapeutic, CX-072
12/14/2016
-
CytomX Announces Selection By Bristol-Myers Squibb Of First Clinical Candidate Probody From Collaboration
12/13/2016
-
CytomX Announces Fourth Target Selection By Bristol-Myers Squibb Under Strategic Oncology Collaboration
12/5/2016
-
CytomX Announces Third Quarter 2016 Financial Results And Provides Pipeline Update
11/4/2016
-
CytomX To Announce Third Quarter 2016 Financial Results
10/27/2016
-
Deal Spree for AbbVie Continues with $500 Million Cancer Tie-Up with Bay Area's CytomX
4/25/2016
-
CytomX Added to Russell 2000 Index
12/21/2015
-
CytomX Selects Probody Drug Conjugate Clinical Candidate, CX-2009, Targeting Highly Expressed Tumor Antigen, CD166
12/11/2015
-
CytomX To Present At Oppenheimer's 26th Annual Healthcare Conference
12/1/2015
-
CytomX Reports Third Quarter 2015 Financial Results
11/23/2015
-
CytomX Highlights Data From Multiple Probody Pipeline Programs At Investor Event During AACR-National Cancer Institute-EORTC Conference
11/9/2015
-
CytomX And MD Anderson Cancer Center Enter Into Strategic Collaboration For Probody-Enabled CAR-NK Cell Therapies
11/6/2015
-
CytomX Appoints Matthew Young To Board Of Directors
11/3/2015
-
Data From AACR's Probody Pipeline To Be Presented At The 2015 CytomX-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
10/27/2015
-
CytomX Announces Closing Of Initial Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares
10/15/2015
-
Analysts Closely Watch Bay Area CytomX's $80 Million IPO
10/9/2015
-
CytomX Announces Pricing Of Initial Public Offering
10/8/2015
-
Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX As Chief Medical Officer
8/27/2015
-
CytomX Announces Management Team Promotions
8/3/2015